Clinical trial
Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab
NCT02309281 is registered in ClinicalTrials.gov with Vista Klinik as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab
- Lead sponsor
- Vista Klinik
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- May 31, 2013
- Completion date
- July 31, 2014
- Enrollment
- 33 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
neovascular age-related macular degeneration